Salvage locoregional therapies for recurrent hepatocellular carcinoma

Table 2 Locoregional therapy and oral agents for recurrent hepatocellular carcinoma

Ref.	Study Design	Treatment	Number of Patients	Outcomes
Wan et al[105]	Retrospective	Recurrent HCC ≤ 5 cm	127 TACE; 127 Sorafenib + TACE	Sorafenib + TACE increased survival time compared to TACE alone (30.7 vs 18.22 mo); Longer duration of Sorafenib when treated with Sorafenib + TACE associated with survival
Peng et al[106]	Retrospective	Recurrent HCC ≤ 7 or five nodules ≤ 3 cm	106 TACE-RFA + Sorafenib; 101 Sorafenib	Longer median overall survival and time to progression for combination therapy
Guo et al[109]	Retrospective	Recurrent HCC	20 TACE+ camrelizumab; 51 TACE	No difference in tumor response, progression-free survival, or overall survival

HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; TACE-RFA: Transarterial chemoembolization and radiofrequency ablatio.